CURATIS N AG
Research CURATIS N AG (CURN) on Bullrun: market cap CHF 103.37M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCURN
- ExchangeSW
- CountrySwitzerland
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyCHF
- Market capCHF 103.37M
- Financial periodFY2025
- RevenueCHF 10.80M
- Revenue growth56.6%
- Net income-CHF 1.42M
- Free cash flow-CHF 2.53M
- Gross margin26.3%
Valuation Snapshot
latest market cap is CHF 103.37M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 10.80M | -CHF 1.42M | -CHF 2.53M | 26.3% | -0.28 | CHF 1.87M | n/a | CHF 46.08M |
| FY2024 | CHF 6.90M | -CHF 4.35M | -CHF 825.00K | 23.0% | -1.49 | CHF 3.01M | CHF 0 | CHF 45.60M |
| FY2023 | CHF 0 | -CHF 49.38M | -CHF 1.89M | n/a | -176.38 | CHF 9.00K | CHF 133.00K | -CHF 312.00K |
| FY2022 | CHF 0 | -CHF 34.73M | -CHF 4.66M | n/a | -221.63 | CHF 1.34M | CHF 3.00M | CHF 6.75M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | CHF 103.37M | n/a | n/a | n/a |
About CURATIS N AG
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.
Related stock research
Other Healthcare stocks
26U (26U)
Sandoz Group AG (D8Y0)
Galderma Group N (GALD)
PolyPeptide Group AG (PPGN)
Galderma Group AG (PY30)
Sandoz Group AG (SDZ)
Siegfried Holding Ltd (SFZN)
Ascom Holding AG (0QON)
Medartis Holding AG (1RU)
MEDACTA GROUP S.A. SF-,10 (6MD)
MOLECULAR PARTNERS SF 1 (6ML)
AC Immune SA (ACIU)
Frequently asked questions
What is CURATIS N AG's market cap?
CURATIS N AG's market capitalization is CHF 103.37M.
What does CURATIS N AG do?
Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases.